168 related articles for article (PubMed ID: 9015065)
1. Detection of focal liver lesions: CT of the hepatobiliary system with gadoxetic acid disodium, or Gd-EOB-DTPA.
Schmitz SA; Häberle JH; Balzer T; Shamsi K; Boese-Landgraf J; Wolf KJ
Radiology; 1997 Feb; 202(2):399-405. PubMed ID: 9015065
[TBL] [Abstract][Full Text] [Related]
2. A prototype liver-specific contrast medium for CT: preclinical evaluation of gadoxetic acid disodium, or Gd-EOB-DTPA.
Schmitz SA; Wagner S; Schuhmann-Giampieri G; Krause W; Wolf KJ
Radiology; 1997 Feb; 202(2):407-12. PubMed ID: 9015066
[TBL] [Abstract][Full Text] [Related]
3. Gd-EOB-DTPA and Yb-EOB-DTPA: two prototypic contrast media for CT detection of liver lesions in dogs.
Schmitz SA; Wagner S; Schuhmann-Giampieri G; Krause W; Bollow M; Wolf KJ
Radiology; 1997 Nov; 205(2):361-6. PubMed ID: 9356615
[TBL] [Abstract][Full Text] [Related]
4. Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence.
Reimer P; Rummeny EJ; Shamsi K; Balzer T; Daldrup HE; Tombach B; Hesse T; Berns T; Peters PE
Radiology; 1996 Apr; 199(1):177-83. PubMed ID: 8633143
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of the liver-specific contrast agent Gd-EOB-DTPA in relation to contrast-enhanced liver imaging in humans.
Schuhmann-Giampieri G; Mahler M; Röll G; Maibauer R; Schmitz S
J Clin Pharmacol; 1997 Jul; 37(7):587-96. PubMed ID: 9243351
[TBL] [Abstract][Full Text] [Related]
6. Hepatic computed tomography and cholangiography by use of gadoxetic acid in healthy cats.
Pilton JL; Chau J; Foo TS; Hall EJ; Martinez-Taboada F; Podadera JM; Makara MA
Am J Vet Res; 2019 Apr; 80(4):385-395. PubMed ID: 30919679
[TBL] [Abstract][Full Text] [Related]
7. Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA.
Vogl TJ; Kümmel S; Hammerstingl R; Schellenbeck M; Schumacher G; Balzer T; Schwarz W; Müller PK; Bechstein WO; Mack MG; Söllner O; Felix R
Radiology; 1996 Jul; 200(1):59-67. PubMed ID: 8657946
[TBL] [Abstract][Full Text] [Related]
8. Dy-EOB-DTPA: tolerance and pharmacokinetics in healthy volunteers and preliminary liver imaging in patients.
Krause W; Mahler M; Hanke B; Milius W; Kaufmann J; Rogalla P; Hamm B
Invest Radiol; 2001 Aug; 36(8):431-44. PubMed ID: 11500593
[TBL] [Abstract][Full Text] [Related]
9. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging.
Hamm B; Staks T; Mühler A; Bollow M; Taupitz M; Frenzel T; Wolf KJ; Weinmann HJ; Lange L
Radiology; 1995 Jun; 195(3):785-92. PubMed ID: 7754011
[TBL] [Abstract][Full Text] [Related]
10. Hepatobiliary enhancement with Gd-EOB-DTPA: comparison of spin-echo and STIR imaging for detection of experimental liver metastases.
Mühler A; Clément O; Vexler V; Berthezène Y; Rosenau W; Brasch RC
Radiology; 1992 Jul; 184(1):207-13. PubMed ID: 1609081
[TBL] [Abstract][Full Text] [Related]
11. Gadolinium-ethoxybenzyl-DTPA, a new liver-specific magnetic resonance contrast agent. Kinetic and enhancement patterns in normal and cholestatic rats.
Clément O; Mühler A; Vexler V; Berthezène Y; Brasch RC
Invest Radiol; 1992 Aug; 27(8):612-9. PubMed ID: 1428739
[TBL] [Abstract][Full Text] [Related]
12. Functional hepatobiliary imaging with gadolinium-EOB-DTPA. A comparison of magnetic resonance imaging and 153gadolinium-EOB-DTPA scintigraphy in rats.
Schmitz SA; Mühler A; Wagner S; Wolf KJ
Invest Radiol; 1996 Mar; 31(3):154-60. PubMed ID: 8675423
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.
Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J
Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212
[TBL] [Abstract][Full Text] [Related]
14. Enhancement characteristics of liver metastases, hepatocellular carcinomas, and hemangiomas with Gd-EOB-DTPA: preliminary results with dynamic MR imaging.
Reimer P; Rummeny EJ; Daldrup HE; Hesse T; Balzer T; Tombach B; Peters PE
Eur Radiol; 1997; 7(2):275-80. PubMed ID: 9038130
[TBL] [Abstract][Full Text] [Related]
15. Hepatic kinetics and magnetic resonance imaging of gadolinium-EOB-DTPA in dogs.
Benness G; Khangure M; Morris I; Warwick A; Burrows P; Vogler H; Weinmann HJ
Invest Radiol; 1996 Apr; 31(4):211-7. PubMed ID: 8721960
[TBL] [Abstract][Full Text] [Related]
16. The target sign in colorectal liver metastases: an atypical Gd-EOB-DTPA "uptake" on the hepatobiliary phase of MR imaging.
Granata V; Catalano O; Fusco R; Tatangelo F; Rega D; Nasti G; Avallone A; Piccirillo M; Izzo F; Petrillo A
Abdom Imaging; 2015 Oct; 40(7):2364-71. PubMed ID: 26105523
[TBL] [Abstract][Full Text] [Related]
17. Gadolinium-ethoxybenzyl-DTPA as a hepatobiliary contrast agent for use in MR cholangiography: results of an in vivo phase-I clinical evaluation.
Bollow M; Taupitz M; Hamm B; Staks T; Wolf KJ; Weinmann HJ
Eur Radiol; 1997; 7(1):126-32. PubMed ID: 9000414
[TBL] [Abstract][Full Text] [Related]
18. Ytterbium- and dysprosium-EOB-DTPA. A new prototype of liver-specific contrast agents for computed tomography.
Krause W; Schuhmann-Giampieri G; Bauer M; Press WR; Muschick P
Invest Radiol; 1996 Aug; 31(8):502-11. PubMed ID: 8854197
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III study.
Bluemke DA; Sahani D; Amendola M; Balzer T; Breuer J; Brown JJ; Casalino DD; Davis PL; Francis IR; Krinsky G; Lee FT; Lu D; Paulson EK; Schwartz LH; Siegelman ES; Small WC; Weber TM; Welber A; Shamsi K
Radiology; 2005 Oct; 237(1):89-98. PubMed ID: 16126918
[TBL] [Abstract][Full Text] [Related]
20. Definition of liver tumors in the presence of diffuse liver disease: comparison of findings at MR imaging with positive and negative contrast agents.
Kuwatsuru R; Brasch RC; Mühler A; Mathur A; Vexler VS; Rosenau W; Mintorovitch J; Berthezene Y; Cohen F; Shames DM
Radiology; 1997 Jan; 202(1):131-8. PubMed ID: 8988202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
